World’s first public dengue immunisation programme starts
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
List view / Grid view
News
Saxenda demonstrates significant improvements in cardiometabolic risk factors
5 April 2016 | By Victoria White
In a three year trial, individuals treated with Saxenda lost more weight (6.1%) than those treated with placebo (1.9%)...
CHMP adopts positive opinion for eribulin in advanced liposarcoma
5 April 2016 | By Victoria White
The European Medicines Agency’s CHMP has adopted a positive opinion for a licence extension for Eisai’s Halaven (eribulin)...
Future proofing – Part 2. PAT – Real time release testing of tablets
4 April 2016 | By Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release?
New data for semaglutide and liraglutide presented at ENDO 2016
2 April 2016 | By Victoria White
Semaglutide significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone...
Paul Whittles takes the reins at Sirius Analytical!
1 April 2016 | By Sirius Analytical
Sirius Analytical are pleased to announce that Paul Whittles has been appointed as its new Managing Director...
Daratumumab combination improves PFS in multiple myeloma study
1 April 2016 | By Victoria White
Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone...
Positive topline results from two Phase III dupilumab studies
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
GSK adopts groundbreaking IP approach to expand access to its medicines
31 March 2016 | By Victoria White
Sir Andrew Witty has set out a series of steps designed to help bring innovative GSK medicines to more people living in the world’s poorest countries...
US opioid market to hit $17.7 billion by 2021, says GBI Research
31 March 2016 | By Victoria White
The US market for opioids will grow from $11 billion in 2014 to $17.7 billion by 2021, according to business intelligence provider GBI Research...
Lilly and Incyte announce results from RA-BEACON baricitinib study
Lilly and Incyte have announced results from the RA-BEACON Phase III study of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA).
FDA grants orphan drug designation to Iomab-B
31 March 2016 | By Victoria White
Actinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant...
Children with cancer to be offered gene testing in personalised treatment initiative
31 March 2016 | By Victoria White
Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment...
NHS England to fund HIV treatment Rezolsta (darunavir/cobicistat)
30 March 2016 | By Victoria White
Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1...
BPL’s Coagadex approved in the EU for hereditary factor X deficiency
30 March 2016 | By Victoria White
Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency...
